Eli Lilly Lowers FY19 Outlook – Quick Facts

While reporting its fourth-quarter financial results on Wednesday, Eli Lilly and Co. (LLY) said it expects the pending acquisition of Loxo Oncology to broaden the scope of its oncology portfolio into precision medicines. The company lowered its financial outlook for fiscal 2019.
RTT – Earnings

BEST DEAL UPDATE: